Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
332 stopped studies mapped to Pancreatobiliary Carcinoma and descendants · 93% state a reason
Over the 332 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03592264 | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 19, 2018 | OBI Pharma, Inc | Little evidence of clinical activity in tumor types enrolled | Enrollment / accrual |
| NCT06199882 | SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma | Phase 2 | suspended | Jan 10, 2024 | Zhejiang Cancer Hospital | Patient recruitment difficulties | Enrollment / accrual |
| NCT04003896 | A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma | Phase 2 | terminated | Jul 1, 2019 | Milton S. Hershey Medical Center | The manufacturer and funder Eli Lilly requested to terminate the study | Drug supply |
| NCT04536077 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | Phase 2 | terminated | Sep 2, 2020 | Washington University School of Medicine | Celldex decision | Other (stated, no rule matched) |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in… | Phase 1 / Phase 2 | terminated | Dec 24, 2020 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT06110598 | CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) | Phase 2 | withdrawn | Oct 31, 2023 | Case Comprehensive Cancer Center | PI left the institution | Investigator |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant… | Phase 1 / Phase 2 | terminated | Oct 3, 2023 | Tango Therapeutics, Inc. | Terminated due to safety | Safety / toxicity |
| NCT04931420 | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive… | Phase 2 | withdrawn | Jun 18, 2021 | University of Chicago | PI left site | Investigator |
| NCT06398587 | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of… | Phase 2 | withdrawn | May 3, 2024 | OHSU Knight Cancer Institute | Sponsor withdrawal | Other (stated, no rule matched) |
| NCT03956056 | Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical… | Phase 1 | terminated | May 20, 2019 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT05009953 | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | Phase 2 | terminated | Aug 18, 2021 | CSPC Ouyi Pharmaceutical Co., Ltd. | Internal strategy change. Not related to safety concerns. | Safety / toxicity |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Phase 1 | terminated | Mar 15, 2023 | Hoffmann-La Roche | Sponsor decision (not related to safety, efficacy or quality). | Safety / toxicity |
| NCT04833959 | Pilot Study of 89-Zr Panitumumab in Pancreas Cancer | Phase 1 | withdrawn | Apr 6, 2021 | Stanford University | Business Decision | Sponsor / business decision |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | N/A | withdrawn | Jul 22, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04584775 | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care | N/A | withdrawn | Oct 14, 2020 | Medical University of Graz | Covid19 Pandemia | COVID-19 / pandemic |
| NCT04843306 | Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients | N/A | terminated | Apr 13, 2021 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Technical difficulties that were not able to be resolved. | Other (stated, no rule matched) |
| NCT03450018 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects…(SLC-0111-17-01) | Phase 1 / Phase 2 | terminated | Mar 1, 2018 | British Columbia Cancer Agency | Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the… | Enrollment / accrual |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2… | Phase 3 | terminated | Dec 12, 2018 | QED Therapeutics, a BridgeBio company | The sponsor has decided to close the study due to the discontinuation of infigratinib development… | Safety / toxicity |
| NCT04088188 | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of… | Phase 1 | terminated | Sep 12, 2019 | Academic and Community Cancer Research United | Low accrual | Enrollment / accrual |
| NCT04390243 | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a… | Phase 2 | terminated | May 15, 2020 | Academic and Community Cancer Research United | Slow accrual | Enrollment / accrual |
| NCT02452970 | RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration…(EPIC) | Phase 2 | terminated | May 25, 2015 | EpicentRx, Inc. | Poor enrollment and adverse event experiences in the limited population | Safety / toxicity |
| NCT06341725 | EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging | — | terminated | Apr 2, 2024 | Paolo Giorgio Arcidiacono, MD | no patients with inclusion criteria | Other (stated, no rule matched) |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT05292443 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated… | — | withdrawn | Mar 23, 2022 | Geneplus-Beijing Co. Ltd. | No participants were enrolled | Enrollment / accrual |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or… | Phase 1 / Phase 2 | terminated | Dec 18, 2017 | Georgetown University | Study closed due to lack of enrollment. | Enrollment / accrual |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT03397342 | MRI Only Radiation Therapy With CPAP | N/A | terminated | Jan 12, 2018 | Albert Einstein College of Medicine | Study terminated prematurely well short of enrollment target. Only 5 health participants were… | Enrollment / accrual |
| NCT00320918 | Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan,… | — | terminated | May 3, 2006 | University of New Mexico | This was a Chart Review only and was entered in the system in error. | Other (stated, no rule matched) |
| NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With… | Phase 1 | terminated | Aug 6, 2019 | Patrick Joseph Loehrer Sr. | Unable to proceed due to Neulasta difficulties and other complications. | Other (stated, no rule matched) |
| NCT05514912 | Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without… | Phase 2 | withdrawn | Aug 25, 2022 | Emory University | PI has decided to terminate this study due to study supporter pulling support on this study. | Other (stated, no rule matched) |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive… | Early Phase 1 | withdrawn | May 3, 2021 | Roswell Park Cancer Institute | Issues recruiting | Enrollment / accrual |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in… | Phase 1 | terminated | May 15, 2018 | Ipsen | Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns | Safety / toxicity |
| NCT05193604 | A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects… | Phase 1 | terminated | Jan 18, 2022 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Terminated due to the adjustment of sponsor's development strategies and pipeline. | Sponsor / business decision |
| NCT05702385 | Clinical Utility Study for Exo-PDAC | N/A | withdrawn | Jan 27, 2023 | Qure Healthcare, LLC | The study sponsor did not wish to proceed with the study | Other (stated, no rule matched) |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable… | Phase 2 | terminated | Jul 12, 2013 | Albert Einstein College of Medicine | Study was terminated due to slower than anticipated accrual | Enrollment / accrual |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic…(RELIANT) | Phase 3 | terminated | Apr 1, 2020 | Corcept Therapeutics | The independent data monitoring committee found no safety issues, however the observed response… | Safety / toxicity |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With… | Phase 2 / Phase 3 | terminated | Aug 26, 2019 | EMD Serono Research & Development Institute, Inc. | Based on a review of data conducted by the Independent Data Monitoring Committee (IDMC), Sponsor… | Sponsor / business decision |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal… | Phase 2 | terminated | Sep 25, 2020 | Zhen Wang, MD | Slow accrual | Enrollment / accrual |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Jul 30, 2021 | Aravive, Inc. | Due to business reasons | Sponsor / business decision |
| NCT02383433 | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | Phase 2 | terminated | Mar 9, 2015 | Case Comprehensive Cancer Center | PI discretion based on low accrual | Enrollment / accrual |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03490760 | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | Phase 2 | terminated | Apr 6, 2018 | Baptist Health South Florida | Slow/poor enrollment | Enrollment / accrual |
| NCT03122106 | Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and… | Phase 1 | terminated | Apr 20, 2017 | Washington University School of Medicine | Loss of funding | Funding |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05435053 | Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer(CHECKPOINT) | Phase 2 | terminated | Jun 28, 2022 | Ismail Gögenur | The study was terminated on the basis on an evaluation of the safety and efficacy of the 9 included… | Safety / toxicity |
| NCT04099888 | PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With…(RELEASE) | Phase 2 | terminated | Sep 23, 2019 | PCI Biotech AS | Recent results from a Phase 3 study are expected to change the standard of care for patients with… | Other (stated, no rule matched) |
| NCT04566133 | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy… | Phase 2 | terminated | Sep 28, 2020 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Oct 17, 2024source: clinicaltrials